Cargando…
Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035237/ https://www.ncbi.nlm.nih.gov/pubmed/32040760 http://dx.doi.org/10.1007/s40261-020-00892-9 |
| _version_ | 1783500024069488640 |
|---|---|
| author | Lyseng-Williamson, Katherine A. |
| author_facet | Lyseng-Williamson, Katherine A. |
| author_sort | Lyseng-Williamson, Katherine A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7035237 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-70352372020-03-06 Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features Lyseng-Williamson, Katherine A. Clin Drug Investig Correction Springer International Publishing 2020-02-10 2020 /pmc/articles/PMC7035237/ /pubmed/32040760 http://dx.doi.org/10.1007/s40261-020-00892-9 Text en © Springer Nature 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
| spellingShingle | Correction Lyseng-Williamson, Katherine A. Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features |
| title | Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features |
| title_full | Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features |
| title_fullStr | Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features |
| title_full_unstemmed | Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features |
| title_short | Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features |
| title_sort | correction to: glucagon-like peptide-1 receptor agonists in type 2 diabetes: their use and differential features |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035237/ https://www.ncbi.nlm.nih.gov/pubmed/32040760 http://dx.doi.org/10.1007/s40261-020-00892-9 |
| work_keys_str_mv | AT lysengwilliamsonkatherinea correctiontoglucagonlikepeptide1receptoragonistsintype2diabetestheiruseanddifferentialfeatures |